Net Sales are expected to increase by 12 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 4,119 crore, according to Kotak.

Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

"For the first time after six consecutive quarters, the pharma companies under our coverage will report double digit YoY growth of 13 percent in revenues,” said HDFC Securities

Aurobindo Pharma Q4 PAT seen up 10.7% YoY to Rs. 570 cr: HDFC Securities

Net Sales are expected to increase by 13.8 percent Y-o-Y (down 5.5 percent Q-o-Q) to Rs. 4,100 crore, according to HDFC Securities.

Aurobindo Q4 PAT seen up 25.3% YoY to Rs. 648.2 cr: Edelweiss

Net Sales are expected to increase by 19 percent Y-o-Y to Rs. 4,334.4 crore, according to Edelweiss.

Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

Aurobindo Pharma may post 18% growth in Q3 profit, US business seen up 12%

Europe and Rest of World sales are likely to grow 15-18 percent YoY while API business is likely to be flat.

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

Weak US sales, INR appreciation to drag earnings; Dr Reddy, Cadila top pick: Edelweiss

The USFDA granted 246 nods in Q3FY18, which is the highest-ever approvals in a single quarter. Cadila Healthcare received 23 and Aurobindo Pharma got 18 approvals.

Aurobindo Pharma Q2 profit seen up 15% to Rs 696 cr, operating margin may grow 110 bps

EBITDA (earnings before interest, tax, depreciation and amortisation) may increase 15.6 percent year-on-year to Rs 1,074.4 crore and margin may expand 110 basis points to 25.7 percent for quarter ended September 2017.

Aurobindo Pharma Q2 PAT seen up 11.1% YoY to Rs. 672.7 cr: Kotak

Net Sales are expected to increase by 6.9 percent Y-o-Y (up 9.7 percent Q-o-Q) to Rs. 4035.4 crore, according to Kotak.

When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results

EU formulations contributed 25 percent to the total revenue registering a growth of 18.1 percent to a Rs.831 crore, led by an acquired business that has seen profitability during the year on the back of increased focus, product pruning and cost efficiencies.

Aurobindo Q4 PAT seen up 6.5% to Rs 616.2 cr: ICICI Securities

Net Sales are expected to increase by 4.6 percent Q-o-Q (up 9.1 percent Y-o-Y) to Rs 4087.6 crore, according to ICICI Securities. Aurobindo to report net profit at 616.2 crore up 6.5% quarter-on-quarter.

Aurobindo Q3 profit seen up 14%, revenue may grow 10% on US biz

Analysts believe lack of high value launches should keep US growth restricted. Drugs such as Nuvigil, Tricor, Valcyte, Vimpat and Vfend generic may drive US business. Within injectables drugs such as Isosulfane Blue may drive hospital sales in US.

Aurobindo Pharma Q3 PAT may dip 3% to Rs 590 cr: HDFC Securities

Net Sales are expected to increase by 4.9 percent Q-o-Q (up 13.3 percent Y-o-Y) to Rs 3960 crore, according to HDFC Securities.

Aurobindo Q3 PAT seen up 3.5% to Rs 611.4 cr: ICICI Securities

Net Sales are expected to increase by 6.8 percent Q-o-Q (up 15.4 percent Y-o-Y) to Rs 4032.4 crore, according to ICICI Securities.

Aurobindo Pharma Q2 PAT seen up 5.8% to Rs 617.3 cr: Centrum

Net Sales are expected to increase by 5.9 percent Q-o-Q (up 18.4 percent Y-o-Y) to Rs 3945.3 crore, according to Centrum.

Rakesh Jhunjhunwala's key questions to Aurobindo MD after Q1 nos

In earnings' conference call, Jhunjhunwala who currently holds 1.12 percent stake in the company threw a volley of questions to the management. The big bull raised questions on Aurobindo Pharma's finance cost, capex, rationale behind investment in vaccines, product launch, potential revenue growth and its fund raising plans.

Aurobindo to see growth in H2; capacity constraints continue: PL

While the numbers have been in-line, the company has headroom for better growth, says Surajit Pal, Pharma analyst at Prabhudas Lilladher. Capacity constraints for approved products continue to weigh on Aurobindo.

Aurobindo Q1 profit seen up 30%, US biz may support revenue

Aurobindo Pharma's profit in April-June quarter may jump 29.6 percent year-on-year to Rs 560.3 crore and revenue is seen rising 15 percent to Rs 3,810.7 crore, according to average of estimates of analysts polled by CNBC-TV18.

Sun Pharma's topline may suffer; like Aurobindo, Glenmark:Expert

Surajit Pal of Prabhudas Lilladher talks about Sun Pharma and Glenmark's June quarter earnings.

Aurobindo Pharma Q1 PAT seen down 4.4% at Rs 538.3 cr: Religare

Sales are expected to (up 12.9 percent Y-o-Y) to Rs 3747.5 crore, according to Religare Research.

Aurobindo Q1 PAT seen up 4.4% to Rs 587.7 cr: Edelweiss

Net Sales are expected to increase by 3.0 percent Q-o-Q (up 16.2 percent Y-o-Y) to Rs 3858.5 crore, according to Edelweiss

Strong pipeline, Europe profits, US to drive Aurobindo growth

BofA-ML has a buy call on the stock and a price target of Rs 1,015. Earlier, the brokerage had a price target of Rs 1,050 and reduction is mainly on account of higher R&D expenses.

A tale of 2 pharma companies: Aurobindo shines, Sun Coughs

Traders cheered Aurobindo's in-line performance by sending the stock nearly 4 percent higher. But they punished Sun Pharma for missing Street estimates across the board by sending the stock down over 6 percent. CNBC-TV18's Ekta Batra and Archana Shukla crunch the numbers.

Aurobindo Q4 profit seen up 40%, US biz may support revenue

US business growth may be aided by more than 30 ANDA launches in the US over last one year while Europe is likely to be subdued due to low growth.